Skip to content
Tenaya Therapeutics, Inc. logo

Tenaya Therapeutics, Inc. (TNYA) Q1 2026 Earnings

TNYA·Reported May 6, 2026·Before market open

Tenaya Therapeutics, Inc. reported Q1 2026 revenue of $225.0K, missed analyst consensus of $7.5M by $7.3M. Diluted EPS came in at $-0.09 (+62.5% YoY).

Revenue
$225.0Kmissed by $7.3M
Consensus: $7.5M
Diluted EPS
$-0.09met estimate
Consensus: $-0.09
SEC

SEC Filings

Financial Snapshot

Trailing eight quarters through Q1 2026

Q1 2026 Earnings FAQ

Common questions about Tenaya Therapeutics, Inc.'s Q1 2026 earnings report.

Tenaya Therapeutics, Inc. (TNYA) reported Q1 2026 earnings on May 6, 2026 before market open.

Tenaya Therapeutics, Inc. reported revenue of $225.0K and diluted EPS of $-0.09 for Q1 2026.

Revenue missed the consensus estimate of $7.5M by $7.3M. EPS beat the consensus estimate of $-0.09 by $0.00.

Compared to the same quarter a year prior, diluted EPS grew 62.5% from $-0.24.

You can read the 8-K earnings release (0001193125-26-208975) and the 10-Q periodic report (0001193125-26-209084) directly on SEC EDGAR. The filing index links above go to sec.gov.